|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
AU2004260884B2
(en)
*
|
2003-07-22 |
2009-11-19 |
Crucell Holland B.V. |
Binding molecules against SARS-coronavirus and uses thereof
|
|
PL2314621T3
(pl)
*
|
2004-05-27 |
2014-08-29 |
Crucell Holland Bv |
Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
|
|
JP4852046B2
(ja)
*
|
2004-10-12 |
2012-01-11 |
クルセル ホランド ベー ヴェー |
癌の治療及び検出に用いる結合分子
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
CA2608058C
(en)
|
2005-05-12 |
2013-09-10 |
Crucell Holland B.V. |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
|
|
US8148085B2
(en)
|
2006-05-15 |
2012-04-03 |
Sea Lane Biotechnologies, Llc |
Donor specific antibody libraries
|
|
DK2027155T3
(en)
*
|
2006-06-06 |
2016-05-09 |
Crucell Holland Bv |
HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
|
|
CA2663388C
(en)
|
2006-09-07 |
2017-01-17 |
Crucell Holland B.V. |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
|
CN102046654A
(zh)
|
2007-03-13 |
2011-05-04 |
胡马斯有限公司 |
针对甲型流感病毒h5n1株系的抗体
|
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
US8542874B2
(en)
*
|
2007-07-11 |
2013-09-24 |
Cairos Technologies Ag |
Videotracking
|
|
US8383121B2
(en)
|
2007-09-13 |
2013-02-26 |
Temasek Life Sciences Laboratory Limited |
Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
|
|
JP5490695B2
(ja)
*
|
2007-09-13 |
2014-05-14 |
テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド |
インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
|
|
EP3524619A1
(en)
|
2007-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
|
ITTO20080204A1
(it)
|
2008-03-17 |
2009-09-18 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
|
|
CA2719201A1
(en)
*
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc. |
Neutralizing molecules to viral antigens
|
|
ITTO20080398A1
(it)
|
2008-05-27 |
2009-11-28 |
Pomona Biotechnologies Llc |
Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
|
|
CA2731686C
(en)
*
|
2008-07-25 |
2020-04-07 |
Institute For Research In Biomedicine |
Neutralizing anti-influenza a virus antibodies and uses thereof
|
|
US8871207B2
(en)
|
2008-07-25 |
2014-10-28 |
Humabs, LLC |
Neutralizing anti-influenza A virus antibodies and uses thereof
|
|
GB0818356D0
(en)
*
|
2008-10-07 |
2008-11-12 |
Istituto Superiore Di Sanito |
Antibodies
|
|
AR073770A1
(es)
*
|
2008-10-20 |
2010-12-01 |
Imclone Llc |
Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
|
|
ES2525346T3
(es)
|
2008-10-22 |
2014-12-22 |
Institute For Research In Biomedicine |
Métodos para producir anticuerpos a partir de células plasmáticas
|
|
WO2010056804A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
|
AU2008365616A1
(en)
*
|
2008-12-24 |
2011-08-11 |
Temasek Life Sciences Laboratory Limited |
Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
|
|
CA2787099A1
(en)
|
2009-03-30 |
2010-10-14 |
Anice C. Lowen |
Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
|
|
US8894997B2
(en)
|
2009-04-30 |
2014-11-25 |
Vanderbilt University |
Monoclonal antibodies to influenza H1N1 virus uses thereof
|
|
KR101790354B1
(ko)
|
2009-05-11 |
2017-10-25 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
|
|
US20120128671A1
(en)
*
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
|
JP5941841B2
(ja)
|
2009-05-26 |
2016-06-29 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
|
|
EP2464383A4
(en)
*
|
2009-08-14 |
2013-02-13 |
Theraclone Sciences Inc |
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
|
|
WO2011044570A2
(en)
*
|
2009-10-09 |
2011-04-14 |
Emory University |
Recombinant antibodies against h1n1 influenza
|
|
WO2011094445A1
(en)
*
|
2010-01-27 |
2011-08-04 |
Massachusetts Institute Of Technology |
Engineered polypeptide agents for targeted broad spectrum influenza neutralization
|
|
US9701723B2
(en)
|
2010-02-18 |
2017-07-11 |
Icahn School Of Medicine At Mount Sinai |
Vaccines for use in the prophylaxis and treatment of influenza virus disease
|
|
CN102791734B
(zh)
*
|
2010-03-08 |
2014-10-15 |
赛特瑞恩股份有限公司 |
源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体
|
|
WO2011123495A1
(en)
|
2010-03-30 |
2011-10-06 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
|
CN102241768B
(zh)
*
|
2010-05-14 |
2013-12-25 |
中国科学院上海生命科学研究院 |
一种抗甲型h1n1流感病毒血凝素蛋白的抗体
|
|
RU2635999C2
(ru)
|
2010-06-17 |
2017-11-17 |
ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи |
Антитела, подходящие для пассивной иммунизации против гриппа
|
|
US9707288B2
(en)
|
2010-07-22 |
2017-07-18 |
John W. Schrader |
Cross-protective pathogen protection, methods and compositions thereof
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2603237A4
(en)
*
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
|
US9534042B2
(en)
|
2010-09-03 |
2017-01-03 |
Fujita Health University |
Influenza virus-neutralizing antibody and screening method therefor
|
|
CA2811103C
(en)
*
|
2010-09-14 |
2020-01-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2663334A4
(en)
*
|
2011-01-10 |
2016-01-13 |
Univ Emory |
ANTIBODIES AGAINST INFLUENZA
|
|
AU2012217867A1
(en)
*
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
JP2014509588A
(ja)
*
|
2011-03-01 |
2014-04-21 |
アムジエン・インコーポレーテツド |
二特異性結合剤
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
EP2721158B1
(en)
|
2011-06-20 |
2017-05-03 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for h1n1 influenza
|
|
EP2731967B1
(en)
|
2011-07-14 |
2016-10-12 |
Janssen Vaccines & Prevention B.V. |
Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
|
|
HUE044089T2
(hu)
|
2011-07-18 |
2019-09-30 |
Inst Res Biomedicine |
Neutralizáló anti-influenza A antitestek és alkalmazásaik
|
|
CA2842860A1
(en)
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies, Llc |
Sur-binding proteins
|
|
US20130084301A1
(en)
*
|
2011-08-30 |
2013-04-04 |
Steven Foung |
Cluster of Neutralizing Antibodies to Hepatitis C Virus
|
|
GB201115214D0
(en)
|
2011-09-02 |
2011-10-19 |
Health Prot Agency |
Influenza virus antibody compositions
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2758075B1
(en)
|
2011-09-20 |
2023-05-03 |
Icahn School of Medicine at Mount Sinai |
Influenza virus vaccines and uses thereof
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
WO2013059524A2
(en)
*
|
2011-10-18 |
2013-04-25 |
Emory University |
Antibodies directed against influenza
|
|
IN2014CN04742A
(enExample)
*
|
2011-11-28 |
2015-09-18 |
Crucell Holland Bv |
|
|
WO2013081463A2
(en)
*
|
2011-12-02 |
2013-06-06 |
Aimm Therapeutics B.V. |
Influenza a virus specific antibodies
|
|
MX367743B
(es)
|
2011-12-05 |
2019-09-04 |
Trellis Bioscience Llc |
Anticuerpos utiles para la inmunizacion pasiva de influenza.
|
|
WO2013089496A1
(ko)
*
|
2011-12-15 |
2013-06-20 |
(주)에이프로젠 |
H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
SG11201404653UA
(en)
|
2012-02-07 |
2014-09-26 |
Univ Pittsburgh |
Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
|
|
CA2863949C
(en)
|
2012-02-13 |
2021-06-29 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
|
|
MX360056B
(es)
|
2012-03-08 |
2018-10-19 |
Janssen Vaccines & Prevention Bv |
Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
MX345150B
(es)
|
2012-03-30 |
2017-01-18 |
Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
US9969794B2
(en)
|
2012-05-10 |
2018-05-15 |
Visterra, Inc. |
HA binding agents
|
|
EP2712626A1
(en)
|
2012-09-28 |
2014-04-02 |
Fabentech |
Passive immunisation against influenza, in particular H5N1
|
|
BR112015010817A8
(pt)
|
2012-11-13 |
2018-01-23 |
Genentech Inc |
anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
IN2015DN03070A
(enExample)
|
2012-11-27 |
2015-10-02 |
Univ Pittsburgh |
|
|
EP2934581B1
(en)
|
2012-12-18 |
2022-09-14 |
Icahn School of Medicine at Mount Sinai |
Influenza virus vaccines and uses thereof
|
|
EP2970397A2
(en)
|
2013-03-14 |
2016-01-20 |
University Of Washington Through Its Center For Commercialization |
Polypeptides for treating and/or limiting influenza infection
|
|
IL241552B2
(en)
|
2013-03-14 |
2023-09-01 |
Contrafect Corp |
Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
|
|
US9908930B2
(en)
|
2013-03-14 |
2018-03-06 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2014161483A1
(zh)
*
|
2013-04-02 |
2014-10-09 |
厦门大学 |
识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
|
|
CN105452270B
(zh)
|
2013-05-30 |
2020-12-01 |
扬森疫苗与预防公司 |
流行性感冒病毒疫苗及其用途
|
|
US20160200799A1
(en)
|
2013-08-23 |
2016-07-14 |
Fujita Health University |
Anti-influenza virus neutralizing antibody
|
|
EP3037819A4
(en)
*
|
2013-08-23 |
2017-03-29 |
Fujita Health University |
Method of determining resistance to influenza virus
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
SG11201602522VA
(en)
|
2013-10-02 |
2016-04-28 |
Medimmune Llc |
Neutralizing anti-influenza a antibodies and uses thereof
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
WO2015068781A1
(ja)
*
|
2013-11-06 |
2015-05-14 |
国立大学法人大阪大学 |
インフルエンザウイルスａ型のグループ１に対して広域な中和活性を有する抗体
|
|
US10639370B2
(en)
|
2014-02-04 |
2020-05-05 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
AU2015214146B2
(en)
|
2014-02-04 |
2020-09-17 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
WO2015120474A1
(en)
|
2014-02-10 |
2015-08-13 |
Igm Biosciences, Inc. |
Iga multi-specific binding molecules
|
|
EP3119804A2
(en)
|
2014-03-19 |
2017-01-25 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
WO2016005480A1
(en)
|
2014-07-10 |
2016-01-14 |
Crucell Holland B.V. |
Influenza virus vaccines and uses thereof
|
|
KR102463632B1
(ko)
|
2014-07-10 |
2022-11-03 |
얀센 백신스 앤드 프리벤션 비.브이. |
인플루엔자 바이러스 백신 및 이의 용도
|
|
WO2016011035A2
(en)
|
2014-07-15 |
2016-01-21 |
Medlmmune, Llc |
Neutralizing anti-influenza b antibodies and uses thereof
|
|
TWI701258B
(zh)
|
2014-12-19 |
2020-08-11 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
JP2018504412A
(ja)
|
2015-01-23 |
2018-02-15 |
アイカーン スクール オブ メディシン アット マウント サイナイ |
インフルエンザウイルスワクチン接種レジメン
|
|
CA2975655C
(en)
|
2015-02-05 |
2023-09-19 |
Janssen Vaccines & Prevention B.V. |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
|
US10174127B2
(en)
|
2015-02-05 |
2019-01-08 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza neuraminidase
|
|
AU2016261299B2
(en)
|
2015-05-11 |
2019-12-05 |
Janssen Vaccines & Prevention B.V. |
Influenza virus neutralizing peptidomimetic compounds
|
|
MX389708B
(es)
|
2015-06-01 |
2025-03-20 |
Medimmune Llc |
Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
|
|
WO2017083627A1
(en)
|
2015-11-13 |
2017-05-18 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
JP2019502715A
(ja)
|
2016-01-13 |
2019-01-31 |
メディミューン，エルエルシー |
Ａ型インフルエンザを治療する方法
|
|
CA3015347A1
(en)
|
2016-02-24 |
2017-08-31 |
Visterra, Inc. |
Formulations of antibody molecules to influenza virus
|
|
US10703803B2
(en)
|
2016-03-01 |
2020-07-07 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza B neuraminidase
|
|
EP3471767A4
(en)
|
2016-06-15 |
2020-01-15 |
Icahn School of Medicine at Mount Sinai |
Influenza virus hemagglutinin proteins and uses thereof
|
|
KR101835009B1
(ko)
|
2016-08-19 |
2018-03-07 |
주식회사 하이딥 |
터치 입력 장치
|
|
AU2017345786B2
(en)
|
2016-10-21 |
2024-08-01 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
US11312761B2
(en)
|
2016-10-21 |
2022-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
WO2018075954A2
(en)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
JP2020500169A
(ja)
|
2016-10-27 |
2020-01-09 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
インフルエンザウイルスを中和する化合物
|
|
CA3051377A1
(en)
|
2017-01-27 |
2018-08-02 |
National Research Council Of Canada |
Hemagglutinin-specific antibodies and uses thereof
|
|
US11040963B2
(en)
|
2017-02-02 |
2021-06-22 |
Janssen Vaccines & Prevention B.V. |
Piperazine derivatives for influenza virus inhibitions
|
|
WO2018141854A1
(en)
|
2017-02-02 |
2018-08-09 |
Janssen Vaccines & Prevention B.V. |
Piperazine derivatives for influenza virus inhibition
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
WO2018187706A2
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
|
WO2019035630A2
(ko)
*
|
2017-08-14 |
2019-02-21 |
사회복지법인 삼성생명공익재단 |
인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편
|
|
JP7035170B2
(ja)
|
2017-09-15 |
2022-03-14 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
|
|
PL3743106T3
(pl)
|
2018-01-23 |
2022-11-14 |
Janssen Vaccines & Prevention B.V. |
Szczepionki przeciwko wirusowi grypy i ich zastosowanie
|
|
SG11202006379UA
(en)
|
2018-01-26 |
2020-07-29 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
CA3090244A1
(en)
*
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
WO2019246363A1
(en)
|
2018-06-21 |
2019-12-26 |
Icahn School Of Medicine At Mount Sinai |
Mosaic influenza virus hemagglutinin polypeptides and uses thereof
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CN111057718A
(zh)
*
|
2018-10-17 |
2020-04-24 |
南京大学 |
一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法
|
|
KR102113302B1
(ko)
*
|
2018-12-24 |
2020-05-20 |
원광대학교산학협력단 |
상보성결정부 기반 조류 인플루엔자 바이러스의 h5 아형에 특이적으로 결합하는 펩티드 및 이의 용도
|
|
EP3946613A1
(en)
|
2019-03-25 |
2022-02-09 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
|
WO2020219719A1
(en)
|
2019-04-24 |
2020-10-29 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
|
JP7865873B2
(ja)
|
2019-09-05 |
2026-05-26 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチン及びその使用
|
|
CN115003328A
(zh)
|
2019-10-22 |
2022-09-02 |
西奈山伊坎医学院 |
重组神经氨酸酶及其用途
|
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
|
CN111440228B
(zh)
*
|
2020-03-09 |
2021-08-24 |
扬州大学 |
多种亚型流感病毒ha2蛋白共同抗原表位、抗体、鉴定方法和应用
|
|
WO2021201677A1
(en)
|
2020-04-01 |
2021-10-07 |
Kiadis Pharma Intellectual Property B.V. |
Compositions and methods targeting influenza
|
|
WO2021216103A1
(en)
*
|
2020-04-20 |
2021-10-28 |
Mahna Satish |
Controlled exposure to pathogens for generating immunity
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
US20240043416A1
(en)
|
2021-02-04 |
2024-02-08 |
Sichuan Haisco Pharmaceutical Co., Ltd. |
Salt and crystal form of ha inhibitor compound
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
TW202309075A
(zh)
*
|
2021-04-30 |
2023-03-01 |
美商亞得捷歐治療公司 |
對冠狀病毒s蛋白質具特異性之化合物及其用途
|
|
US20260183380A1
(en)
|
2022-11-14 |
2026-07-02 |
Janssen Vaccines & Prevention B.V. |
Influenza b virus vaccines and uses thereof
|
|
WO2025019631A1
(en)
|
2023-07-19 |
2025-01-23 |
Icahn School Of Medicine At Mount Sinai |
Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
|
|
TW202527960A
(zh)
|
2023-09-06 |
2025-07-16 |
美商賽諾菲巴斯德公司 |
經修飾ｂ型流感血球凝集素多肽及核酸及其用途
|
|
WO2025090499A1
(en)
*
|
2023-10-24 |
2025-05-01 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Monoclonal antibodies that bind an antigen of epithelial ovarian cancer and their use
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2026027730A1
(en)
|
2024-07-31 |
2026-02-05 |
Sanofi |
Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026052773A1
(en)
|
2024-09-06 |
2026-03-12 |
Sanofi |
Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
|